Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT

Health Technology Assessment : HTA
Peter J D AndrewsGordon D Murray

Abstract

Traumatic brain injury (TBI) is a major cause of disability and death in young adults worldwide. It results in around 1 million hospital admissions annually in the European Union (EU), causes a majority of the 50,000 deaths from road traffic accidents and leaves a further ≈10,000 people severely disabled. The Eurotherm3235 Trial was a pragmatic trial examining the effectiveness of hypothermia (32-35 °C) to reduce raised intracranial pressure (ICP) following severe TBI and reduce morbidity and mortality 6 months after TBI. An international, multicentre, randomised controlled trial. Specialist neurological critical care units. We included adult participants following TBI. Eligible patients had ICP monitoring in place with an ICP of > 20 mmHg despite first-line treatments. Participants were randomised to receive standard care with the addition of hypothermia (32-35 °C) or standard care alone. Online randomisation and the use of an electronic case report form (CRF) ensured concealment of random treatment allocation. It was not possible to blind local investigators to allocation as it was obvious which participants were receiving hypothermia. We collected information on how well the participant had recovered 6 months after injury. T...Continue Reading

References

Sep 1, 1990·Journal of Neuropathology and Experimental Neurology·W D DietrichI Valdes
Mar 1, 1990·Anesthesiology·J P Morray, E G Pavlin
Jul 1, 1989·Stroke; a Journal of Cerebral Circulation·R BustoM D Ginsberg
Jul 1, 1995·The Journal of Thoracic and Cardiovascular Surgery·C K RokkasN T Kouchoukos
Jan 1, 1994·Neurosurgical Review·L CervoniR Delfini
Sep 1, 1993·The American Journal of Physiology·J W KuluzR Busto
Jan 1, 1993·Journal of Neurotrauma·G L CliftonS C Choi
Apr 1, 1993·Molecular and Chemical Neuropathology·B G LyethL W Jenkins
Feb 20, 1997·The New England Journal of Medicine·D W MarionS T DeKosky
Mar 1, 1996·Metabolic Brain Disease·K KumarA T Evans
Aug 4, 1998·Journal of Neurosurgery·T ShiozakiT Shimazu
Nov 10, 1998·Experimental Brain Research·Y TohyamaY Yonemasu
Apr 1, 1997·Bulletin of the American College of Surgeons·J E Wilberger
May 18, 1999·Cardiovascular Research·R ScotlandA Ahluwalia
Jan 12, 2000·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·G Van Den Berghe
Oct 19, 2000·Lancet·J Ghajar
Nov 1, 2000·Critical Care : the Official Journal of the Critical Care Forum·S A BernardM Buist
Feb 24, 2001·The New England Journal of Medicine·G L CliftonM Schwartz
May 17, 2001·Journal of Neurosurgery·K H PoldermanA R Girbes

❮ Previous
Next ❯

Citations

Oct 26, 2018·JAMA : the Journal of the American Medical Association·Annemarie DochertyPeter J D Andrews
Jan 14, 2020·Therapeutic Hypothermia and Temperature Management·Neeraj BadjatiaPeter Andrews
Sep 30, 2019·Journal of Neurology·Abdelhakim KhellafAdel Helmy
Jan 31, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neel S SinghalDengke K Ma
Feb 6, 2019·Frontiers in Neurology·Anelia A Y KassiShyam Gajavelli
Dec 8, 2021·Minerva anestesiologica·Camilla Gelormini, Anselmo Caricato
Aug 3, 2021·Minerva anestesiologica·Chiara RobbaFabio S Taccone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Canavan Disease

Canavan disease, a type of leukodystrophy, is an autosomal recessive neurodegenerative disorder, and is one of the most common degenerative cerebral diseases of infancy. Discover the latest research on Canavan disease here.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.